Cancer
Childhood Solid Neoplasm
CI-CAN-00000138Explore in graph →
PediatricNon-malignant22 active trials
- NCIt
- C9107
Loading cancer entity…
Cancer
CI-CAN-00000138Explore in graph →
Clinical trials
215 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00994500 | Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00016861 | Irinotecan in Treating Children With Refractory or Progressive Solid Tumors | completed | Phase 1 | — | Texas Children's Cancer CenterOTHER | 1 | Jun 26, 2013 | clinicaltrials |
| NCT00513981 | High-Dose Methotrexate in Treating Young Patients With Solid Tumors | completed | Phase 1 | 36 | Children's Cancer and Leukaemia GroupOTHER | 2 | Jun 26, 2013 | clinicaltrials |
| NCT00003630 | Arsenic Trioxide in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00068471 | Anidulafungin in Treating Immunocompromised Children With Neutropenia | completed | Phase 1 / Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00079404 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00085111 | Bevacizumab in Treating Young Patients With Refractory Solid Tumors | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00101270 | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00070421 | Study of @neWorld: A Virtual Community for Children With Cancer | completed | Phase 1 / Phase 2 | — | Leap of Faith TechnologiesINDUSTRY | 1 | May 15, 2013 | clinicaltrials |
| NCT00281944 | Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00024284 | Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors | completed | Phase 1 | — | Bristol-Myers SquibbINDUSTRY | 2 | Apr 5, 2013 | clinicaltrials |
| NCT00003191 | Fenretinide in Treating Children With Solid Tumors | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2013 | clinicaltrials |
| NCT00003288 | Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 2 | Feb 5, 2013 | clinicaltrials |
| NCT00003370 | Irofulven in Treating Children With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 3 | Feb 5, 2013 | clinicaltrials |
| NCT00005577 | Gemcitabine in Treating Children With Refractory Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 2 | Feb 5, 2013 | clinicaltrials |
| NCT00316953 | Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Feb 5, 2013 | clinicaltrials |
| NCT00005973 | BMS-214662 in Treating Patients With Solid Tumors | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00040781 | Gefitinib in Treating Children With Refractory Solid Tumors | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00039481 | Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00053963 | FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00363272 | Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00005844 | Oxaliplatin in Treating Children With Advanced Solid Tumors | completed | Phase 1 | 26 | St. Jude Children's Research HospitalOTHER | 1 | Oct 23, 2012 | clinicaltrials |
| NCT00004212 | DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | — | Daiichi SankyoINDUSTRY | 1 | May 16, 2012 | clinicaltrials |
| NCT00253474 | PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma | completed | Phase 1 | 36 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 29, 2012 | clinicaltrials |
| NCT00030108 | Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy | completed | Phase 1 | 30 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 15, 2012 | clinicaltrials |
| NCT00036959 | ABT-751 in Treating Young Patients With Refractory Solid Tumors | completed | Phase 1 | 90 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 15, 2012 | clinicaltrials |
| NCT00303940 | Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors | completed | Phase 1 | 26 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 15, 2012 | clinicaltrials |
| NCT00990912 | A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002) | completed | Phase 1 / Phase 2 | 20 | Bristol-Myers SquibbINDUSTRY | 0 | Feb 5, 2010 | clinicaltrials |
Data updated 23 days agoSource updated Jul 2, 2013source: clinicaltrials